Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8784882 | ACERUS | Controlled release delivery system for nasal applications and method of treatment |
Feb, 2024
(10 months from now) | |
US8877230 | ACERUS | Controlled release delivery system for nasal applications |
Feb, 2024
(10 months from now) | |
US8574622 | ACERUS | Controlled release delivery system for nasal applications |
Feb, 2024
(10 months from now) | |
US8784869 | ACERUS | Controlled release delivery system for nasal applications and methods of treatment |
Feb, 2024
(10 months from now) | |
US11090312 | ACERUS | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
Mar, 2034
(10 years from now) |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 28 May, 2014
Treatment: A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of testosterone gel formulation.; Nasal administrat...
Dosage: GEL, METERED;NASAL
32
United States
2
IB
2
European Union
1
South Africa
1
Denmark
1
Austria
1
Australia
1
Russia
1
Slovenia
1
Norway
1
Germany
1
Argentina
1
Brazil
1
Croatia
1
Portugal
1
Malaysia
1
Spain
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
Japan
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic